Newman Dignan & Sheerar, Inc. Medicenna Therapeutics Corp. Transaction History

Newman Dignan & Sheerar, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$0.16 - $0.44 $2,066 - $5,682	12,915 New	12,915 $3,000
Q3 2022 Oct 18, 2022	BUY	$0.83 - $1.78 $10,719 - $22,988	12,915 New	12,915 $11,000
Q2 2022 Aug 03, 2022	SELL	$0.79 - $1.32 $10,202 - $17,047	-12,915 Closed	0 $0
Q1 2022 Apr 14, 2022	SELL	$1.26 - $1.92 $1,260 - $1,920	-1,000 Reduced 7.19%	12,915 $17,000
Q4 2021 Jan 18, 2022	BUY	$1.53 - $2.85 $1,530 - $2,850	1,000 Added 7.74%	13,915 $23,000
Q3 2021 Oct 07, 2021	BUY	$1.91 - $3.05 $24,667 - $39,390	12,915 New	12,915 $36,000

863K

Ticker MDNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,637,504
Market Cap $21.6M
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as...

Get notified when there are updates to the investment portfolio of Newman Dignan & Sheerar, Inc., based on Form 13F filings with the SEC.

Stay updated on Newman Dignan & Sheerar, Inc. with notifications on news.